Stem cell transplantation and gene therapy for HIV-related lymphomas.
The treatment of patients with HIV-related non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) is less successful than in the non-HIV setting, in part due to the aggressive character of these lymphomas but also due to the underlying HIV infection. High-dose therapy with stem cell transplantation has been used with success in the HIV-negative lymphoma setting for high-risk or relapsed disease. However, for patients with HIV-NHL and HIV-HD, ultimately the chance for long-term lymphoma-free survival also depends on successful control of the HIV infection. Gene therapy approaches may provide the opportunity for this long-term control. Herein, we describe the use of high-dose chemotherapy with stem cell rescue in conjunction with current and future gene therapy approaches for the treatment of HIV-associated lymphomas.
Krishnan
Amrita
A
Division of Hematology and Bone Marrow Transplantation, and Department of Virology, City of Hope National Medical Center, Duarte, CA 91010, USA. akrishnan@coh.org
Zaia
John
J
Molina
Arturo
A
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018572:Disease-Free Survival; D015316:Genetic Therapy; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000628:therapy*; D033581:Stem Cell Transplantation; D013997:Time Factors
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents